The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks : a review of two placebo-controlled phase II trials. / Tfelt-Hansen, Peer C; Olesen, Jes.

I: Journal of Headache and Pain, Bind 13, Nr. 4, 2012, s. 271-5.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Tfelt-Hansen, PC & Olesen, J 2012, 'The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials', Journal of Headache and Pain, bind 13, nr. 4, s. 271-5. https://doi.org/10.1007/s10194-012-0428-7

APA

Tfelt-Hansen, P. C., & Olesen, J. (2012). The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. Journal of Headache and Pain, 13(4), 271-5. https://doi.org/10.1007/s10194-012-0428-7

Vancouver

Tfelt-Hansen PC, Olesen J. The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. Journal of Headache and Pain. 2012;13(4):271-5. https://doi.org/10.1007/s10194-012-0428-7

Author

Tfelt-Hansen, Peer C ; Olesen, Jes. / The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks : a review of two placebo-controlled phase II trials. I: Journal of Headache and Pain. 2012 ; Bind 13, Nr. 4. s. 271-5.

Bibtex

@article{f14b96e0c33b42f58ecb425fe2cc36dc,
title = "The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials",
abstract = "Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P ",
author = "Tfelt-Hansen, {Peer C} and Jes Olesen",
year = "2012",
doi = "10.1007/s10194-012-0428-7",
language = "English",
volume = "13",
pages = "271--5",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks

T2 - a review of two placebo-controlled phase II trials

AU - Tfelt-Hansen, Peer C

AU - Olesen, Jes

PY - 2012

Y1 - 2012

N2 - Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P 

AB - Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P 

U2 - 10.1007/s10194-012-0428-7

DO - 10.1007/s10194-012-0428-7

M3 - Journal article

C2 - 22430431

VL - 13

SP - 271

EP - 275

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 4

ER -

ID: 40186358